Navigation Links
Kyowa Hakko’s Citicoline Obtains Novel Food Registration status in Europe
Date:7/17/2014

New York, NY (PRWEB) July 17, 2014

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI), concluding on October 2013 that Citicoline is safe under the proposed uses and use levels. http://www.efsa.europa.eu/it/efsajournal/doc/3421.pdf

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorizing Kyowa Hakko the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_196_R_0006&from=EN )

Citicoline is intended to be used in food supplements in Europe aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1,000 mg/day.

Citicoline is the generic name for CDP-choline (choline cytidine 5’-pyrophosphate), organic molecule produced endogenously and found in all living cells. Is a source of choline and precursor for the synthesis of phospholipids that are essential constituents of cell membranes, including phosphatidylcholine, phosphatidylserine and phosphatidyl-ethanolamine.

In United States, under Cognizin® brand name, Kyowa Hakko USA, Inc. has been marketing Citicoline since the early 1980’s as dietary supplement and created the trademark name in 2004, received self-affirmed Generally Recognized As Safe (GRAS) status in 2009, as food ingredient for use at levels of 250 mg per serving in such products as dietary supplements, beverages, breakfast cereals, chewing gum, pastas, hard candies, milk products, fruit juices and soft candy.

Cognizin® Citicoline is often called a “brain nutrient” because it increases levels of several important neurotransmitters including acetylcholine, dopamine and noradrenaline; helps maintain the integrity of neuronal cell membranes and increases energy production in the frontal cortex.

About Cognizin® Citicoline
A proprietary form of Citicoline, Cognizin® is a potent brain-health nutrient that’s been clinically studied to support mental energy, focus, attention and recall. Tested in human clinical trials and developed using a patented fermentation process, Cognizin® is a pure, allergen-free GRAS ingredient that’s stable and effective.
For more information on Cognizin®, go to http://www.cognizin.com

About Kyowa Hakko Europe
Kyowa Hakko Europe and Kyowa Hakko Bio Italia are the Central-North and South European sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit http://www.kyowa.eu or email at finechemicals(at)kyowa(dot)it

About Kyowa Hakko USA
Kyowa Hakko USA is the North American sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information visit http://www.kyowa-usa.com

# # #

Read the full story at http://www.prweb.com/releases/2014/07/prweb12027397.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Citicoline Supplement Doesnt Help Treat Brain Injury, Study Finds
2. Petra Beli joins IMB, obtains Emmy Noether award to study cellular response to DNA damage
3. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
4. Albertson & Davidson, LLP Obtains Court Order Requiring California Trustee to Provide Pre-Death Accounting
5. Tanimura & Antle Artisan® Lettuce Obtains American Heart Association Heart-Check Food Certification
6. Car Accident Victim Obtains $1.9 Million Settlement from Insurance Company, Says Washington D.C. Personal Injury Attorney Mike Slocumb
7. NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
8. NUS researchers discover novel protein complex with potential to combat gastric cancer
9. New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
10. Molecular imaging finds novel way to knock down breast cancer
11. Researchers at the Gladstone Institutes find novel approach to reactivate latent HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... As part ... Museum today to honor the victims of the Holocaust and Nazi persecution, Center ... at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... The ... $1.6 million in charitable dental services to 1,961 people during the April 22-23 event ... at no charge to Californians who experience barriers to care, CDA Cares educates the ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: